2024
Asparagine synthetase and G‐protein coupled estrogen receptor are critical responders to nutrient supply in KRAS mutant colorectal cancer
Lu L, Zhang Q, Aladelokun O, Berardi D, Shen X, Marin A, Garcia‐Milian R, Roper J, Khan S, Johnson C. Asparagine synthetase and G‐protein coupled estrogen receptor are critical responders to nutrient supply in KRAS mutant colorectal cancer. International Journal Of Cancer 2024 PMID: 39039782, DOI: 10.1002/ijc.35104.Peer-Reviewed Original ResearchG protein-coupled estrogen receptor 1KRAS mutant colorectal cancerAsparagine synthetase expressionMutant colorectal cancerColorectal cancerAsparagine synthetaseG-protein coupled estrogen receptor 1 expressionG protein-coupled estrogen receptorWild-typeAssociated with poor overall survivalAdvanced stage tumorsKRAS wild-typeProtective effect of estradiolEffects of estradiolPoor overall survivalEstrogen receptor 1Expression of asparagine synthetasePresence of estradiolIncreased caspase-3 activityDepletion inhibited cell growthColon cancer cohortNutrient supplyAdvanced tumorsOverall survivalStage tumorsImmunotherapy utilization in stage IIIA melanoma: less may be more
Frey A, Kerekes D, Khan S, Tran T, Kluger H, Clune J, Ariyan S, Sznol M, Ishizuka J, Olino K. Immunotherapy utilization in stage IIIA melanoma: less may be more. Frontiers In Oncology 2024, 14: 1336441. PMID: 38380358, PMCID: PMC10876869, DOI: 10.3389/fonc.2024.1336441.Peer-Reviewed Original ResearchStage IIIA melanomaHigh-volume centersRisk-adjusted survivalLow-volume centersImmunotherapy utilizationAdjuvant immunotherapyStage IIIATreatment of stage III melanomaAcademic centersMultivariable Cox proportional hazards regressionStage III melanomaNational Cancer DatabaseStage III diseaseFactors associated with receiptCox proportional hazards regressionCompare patient outcomesProportional hazards regressionIII melanomaImmunotherapy receiptReceiving immunotherapyIII diseaseImmunotherapy agentsOverall survivalSurvival benefitAdjuvant treatment
2023
Surgical treatment of stage IV gastroenteropancreatic neuroendocrine carcinoma: Experience and outcomes in the United States
Kerekes D, Frey A, Bakkila B, Kunstman J, Khan S. Surgical treatment of stage IV gastroenteropancreatic neuroendocrine carcinoma: Experience and outcomes in the United States. Journal Of Surgical Oncology 2023, 128: 790-802. PMID: 37435780, DOI: 10.1002/jso.27392.Peer-Reviewed Original ResearchConceptsGastroenteropancreatic neuroendocrine carcinomasGEP-NECSingle-site surgeryOverall survivalSurgical treatmentNeuroendocrine carcinomaMortality reductionSite surgeryPrimary siteNational Cancer DatabaseRetrospective cohort studyPrimary tumor typeSurgical resectionCohort studyAggressive diseaseSurgical interventionSurvival outcomesTreatment optionsCancer DatabaseSurgeryPatientsTumor typesNECStrongest predictorCarcinomaDiscovery of decreased ferroptosis in male colorectal cancer patients with KRAS mutations
Yan H, Talty R, Jain A, Cai Y, Zheng J, Shen X, Muca E, Paty P, Bosenberg M, Khan S, Johnson C. Discovery of decreased ferroptosis in male colorectal cancer patients with KRAS mutations. Redox Biology 2023, 62: 102699. PMID: 37086630, PMCID: PMC10172914, DOI: 10.1016/j.redox.2023.102699.Peer-Reviewed Original ResearchConceptsKRAS mutant tumorsMale CRC patientsCRC patientsMale patientsKRAS mutationsMutant tumorsOverall survivalMale colorectal cancer patientsKRAS wild-type tumorsAberrant tumor metabolismColorectal cancer patientsCRC patient cohortsColorectal cancer casesFerroptosis-related genesWild-type tumorsNovel potential avenuesNormal colon tissuesPoor OSKRAS statusAdverse outcomesCRC cellsPatient cohortCancer patientsType tumorsCancer casesHepatopancreatobiliary malignancies: time to treatment matters
Kerekes D, Frey A, Bakkila B, Johnson C, Becher R, Billingsley K, Khan S. Hepatopancreatobiliary malignancies: time to treatment matters. Journal Of Gastrointestinal Oncology 2023, 0: 0-0. PMID: 37201090, PMCID: PMC10186552, DOI: 10.21037/jgo-22-1067.Peer-Reviewed Original ResearchTreatment initiationStage IHPB cancersStage I pancreatic cancerExtrahepatic bile duct cancerKaplan-Meier survival analysisHPB cancer patientsNational Cancer DatabaseRetrospective cohort studyBile duct cancerMedian treatment initiationHepatopancreatobiliary cancersMedian survivalCohort studyDuct cancerOverall survivalHispanic patientsEHBD cancerOncologic careBile ductCox regressionBlack raceCancer patientsDefinitive carePancreatic cancer
2022
Bile acid distributions, sex-specificity, and prognosis in colorectal cancer
Cai Y, Shen X, Lu L, Yan H, Huang H, Gaule P, Muca E, Theriot CM, Rattray Z, Rattray NJW, Lu J, Ahuja N, Zhang Y, Paty PB, Khan SA, Johnson CH. Bile acid distributions, sex-specificity, and prognosis in colorectal cancer. Biology Of Sex Differences 2022, 13: 61. PMID: 36274154, PMCID: PMC9590160, DOI: 10.1186/s13293-022-00473-9.Peer-Reviewed Original ResearchConceptsLeft-sided colon tumorsRight-sided colon tumorsColon cancer patientsColorectal cancerTumor locationBile acidsColon tumorsCancer patientsQuantitative immunofluorescencePrimary tumor locationImmune regulatory cellsRecurrence-free survivalBile acid metabolismSecondary bile acidsBile acid distributionBile acid analysisBackgroundBile acidsOverall survivalRegulatory cellsCRC patientsMale patientsPatient sexImmune cellsPatient prognosisImmune responseAsparagine Metabolism in Tumors Is Linked to Poor Survival in Females with Colorectal Cancer: A Cohort Study
Shen X, Cai Y, Lu L, Huang H, Yan H, Paty PB, Muca E, Ahuja N, Zhang Y, Johnson CH, Khan SA. Asparagine Metabolism in Tumors Is Linked to Poor Survival in Females with Colorectal Cancer: A Cohort Study. Metabolites 2022, 12: 164. PMID: 35208238, PMCID: PMC8875032, DOI: 10.3390/metabo12020164.Peer-Reviewed Original ResearchRecurrence-free survivalOverall survivalColorectal cancer prognosisPoor overall survivalPrimary tumor tissuesTumor metabolomeUnique metabolite profilesCohort studyCRC patientsCRC treatmentFemale patientsPoor prognosisColorectal cancerPrognostic disadvantagePatient outcomesPoor survivalSurgical colectomySex-specific differencesCox proportionalEleven metabolitesUntargeted metabolomics analysisCancer prognosisStage ITumor tissueSignificant sex differences
2020
Gene Alterations of N6‐Methyladenosine (m6A) Regulators in Colorectal Cancer: A TCGA Database Study
Zhang Q, Cai Y, Kurbatov V, Khan SA, Lu L, Zhang Y, Johnson CH. Gene Alterations of N6‐Methyladenosine (m6A) Regulators in Colorectal Cancer: A TCGA Database Study. BioMed Research International 2020, 2020: 8826456. PMID: 33415160, PMCID: PMC7769650, DOI: 10.1155/2020/8826456.Peer-Reviewed Original ResearchMeSH KeywordsAdenosineAgedAlpha-Ketoglutarate-Dependent Dioxygenase FTOColorectal NeoplasmsDatabases, GeneticDisease-Free SurvivalDNA Copy Number VariationsFemaleGene Expression Regulation, NeoplasticGenes, NeoplasmHumansMaleMultivariate AnalysisMutationNerve Tissue ProteinsPrognosisProportional Hazards ModelsRNA Splicing FactorsRNA, MessengerConceptsDisease-free survivalImmune cell infiltrationM6A regulatorsCRC patientsCRC casesCell infiltrationMRNA expressionWorse overall survivalN6-methyladenosine regulatorsMicrosatellite instability statusMessenger RNA expressionCancer Genome AtlasOverall survivalColorectal cancerCRC tissuesDatabase studyImmune functionInstability statusColon tissuesRole of m6AGene alterationsRNA expressionCRCGenome AtlasGenetic mutationsAssociation of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival
Heller DR, Nicolson NG, Ahuja N, Khan S, Kunstman JW. Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival. JAMA Surgery 2020, 155: e195047. PMID: 31800002, PMCID: PMC6902102, DOI: 10.1001/jamasurg.2019.5047.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaNational Cancer DatabaseWhite patientsBlack patientsAdvanced diseaseOverall survivalClinical parametersDisease stageCancer DatabaseSurgical proceduresMultivariable Cox proportional hazards regression modelingTreatment inequitiesCox proportional hazards regression modelingPancreatic ductal adenocarcinoma (PDAC) survivalUnadjusted median overall survivalYounger ageProportional hazards regression modelingMedian overall survivalModest survival advantageStage II diseaseNew cancer diagnosesLess chemotherapyResectable cancerCohort studyPrimary outcome
2019
Hepatocellular carcinoma: Impact of academic setting and hospital volume on patient survival
Uhlig J, Sellers CM, Khan SA, Cha C, Kim HS. Hepatocellular carcinoma: Impact of academic setting and hospital volume on patient survival. Surgical Oncology 2019, 31: 111-118. PMID: 31654956, DOI: 10.1016/j.suronc.2019.10.009.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularCombined Modality TherapyDatabases, FactualFemaleFollow-Up StudiesHepatectomyHospitals, High-VolumeHospitals, Low-VolumeHumansLiver NeoplasmsLiver TransplantationMaleMiddle AgedPractice Patterns, Physicians'PrognosisRetrospective StudiesSurvival RateConceptsOverall survivalHepatocellular carcinomaAcademic centersHospital volumePatient survivalInterventional oncologyYoung African American patientsHigh-volume academic centersMultivariable Cox regressionFirst-line treatmentLow-volume centersLonger patient survivalAfrican American patientsHCC treatment modalitiesNon-academic centersLiver transplantMultivariable adjustmentPatient demographicsSurgical resectionLine treatmentCox regressionPotential confoundersVolume centersTreatment modalitiesAmerican patientsDigital Inference of Immune Microenvironment Reveals Low-Risk Subtype of Early Lung Adenocarcinoma
Kurbatov V, Balayev A, Saffarzadeh A, Heller DR, Boffa DJ, Blasberg JD, Lu J, Khan SA. Digital Inference of Immune Microenvironment Reveals Low-Risk Subtype of Early Lung Adenocarcinoma. The Annals Of Thoracic Surgery 2019, 109: 343-349. PMID: 31568747, DOI: 10.1016/j.athoracsur.2019.08.050.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma of LungAdultAgedCohort StudiesDatabases, FactualDisease-Free SurvivalFemaleHumansImmunotherapyKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingPneumonectomyPrognosisProportional Hazards ModelsRetrospective StudiesRisk AssessmentSurvival AnalysisTumor MicroenvironmentConceptsTumor immune microenvironmentImmune microenvironmentLung adenocarcinomaOverall survivalRisk groupsMast cellsCox proportional hazard modelingEarly-stage lung adenocarcinomaLow-risk subtypesKaplan-Meier analysisPathological staging systemProportional hazard modelingImproved clinical outcomesCancer immune microenvironmentImmune cell typesEarly lung adenocarcinomaActivation stateClinical outcomesValidation cohortMacrophage contentStaging systemMultivariable modelCIBERSORT analysisPatientsClinical decisionPractice Patterns and Guideline Non-Adherence in Surgical Management of Appendiceal Carcinoid Tumors
Heller DR, Jean RA, Luo J, Kurbatov V, Grisotti G, Jacobs D, Chiu AS, Zhang Y, Khan SA. Practice Patterns and Guideline Non-Adherence in Surgical Management of Appendiceal Carcinoid Tumors. Journal Of The American College Of Surgeons 2019, 228: 839-851. PMID: 30898583, PMCID: PMC6751559, DOI: 10.1016/j.jamcollsurg.2019.02.050.Peer-Reviewed Original ResearchConceptsNational Comprehensive Cancer Network guidelinesAge 65 yearsAppendiceal carcinoid tumorsAppendiceal carcinoidsLarge tumorsPractice patternsOverall survivalCarcinoid tumorsSurgical managementNetwork guidelinesProcedure typeSmall tumorsHistory of malignancyNational Cancer DatabaseNational practice patternsMultivariable logistic regressionImpact of guidelinesCox proportional hazardsAggressive resectionLymphovascular invasionClinical factorsTreatment guidelinesTumor sizePatient groupNon-AdherenceDoes sentinel lymph node status have prognostic significance in patients with acral lentiginous melanoma?
Pavri SN, Han G, Khan S, Han D. Does sentinel lymph node status have prognostic significance in patients with acral lentiginous melanoma? Journal Of Surgical Oncology 2019, 119: 1060-1069. PMID: 30883783, DOI: 10.1002/jso.25445.Peer-Reviewed Original ResearchConceptsSentinel lymph node biopsyMelanoma-specific survivalAcral lentiginous melanomaSLN metastasisOverall survivalPositive SLNMultivariable analysisLentiginous melanomaALM casesSentinel lymph node statusClark level IVLymph node biopsyLymph node statusWorse overall survivalSignificant prognostic informationSLNB statusUlceration statusNegative SLNStudy patientsNode biopsyPrognostic benefitSEER databaseSLN statusMedian ageClinicopathological factorsIntrahepatic Cholangiocarcinoma: Socioeconomic Discrepancies, Contemporary Treatment Approaches and Survival Trends from the National Cancer Database
Uhlig J, Sellers CM, Cha C, Khan SA, Lacy J, Stein SM, Kim HS. Intrahepatic Cholangiocarcinoma: Socioeconomic Discrepancies, Contemporary Treatment Approaches and Survival Trends from the National Cancer Database. Annals Of Surgical Oncology 2019, 26: 1993-2000. PMID: 30693451, DOI: 10.1245/s10434-019-07175-4.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseIntrahepatic cholangiocarcinomaOverall survivalMedicaid insuranceCancer DatabaseLonger survivalTreatment allocationSurvival trendsTreatment approachesInterventional oncologySocioeconomic discrepanciesHigher surgery ratesMultivariable Cox modelFirst-line treatmentCurrent treatment approachesContemporary treatment approachesLow incomeMale African AmericansEligible patientsMethodsThe 2004ICC patientsSurgery ratesMale sexTreatment predictorsCancer stage
2018
Clinical impact of underutilization of adjuvant therapy in node positive gastric adenocarcinoma
Zhu R, Liu F, Grisotti G, Perez-Irizarry J, Salem RR, Cha CH, Johung KL, Boffa DJ, Zhang Y, Khan SA. Clinical impact of underutilization of adjuvant therapy in node positive gastric adenocarcinoma. Journal Of Gastrointestinal Oncology 2018, 9: 517-526. PMID: 29998017, PMCID: PMC6006033, DOI: 10.21037/jgo.2018.03.05.Peer-Reviewed Original ResearchPost-operative chemoradiationPeri-operative chemotherapyNode-positive gastric cancerAdjuvant therapyPositive gastric cancerGastric adenocarcinomaAdjuvant chemotherapyGastric cancerCurative-intent gastrectomyNational Cancer DatabasePercentage of patientsThird of patientsMean survival timeMultimodality careCurative gastrectomyOverall survivalSurgical resectionCancer outcomesCancer DatabasePoor survivalClinical impactLong-term effectsRadiation therapySurvival advantageSurvival timeIntegrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis
Pitroda SP, Khodarev NN, Huang L, Uppal A, Wightman SC, Ganai S, Joseph N, Pitt J, Brown M, Forde M, Mangold K, Xue L, Weber C, Segal JP, Kadri S, Stack ME, Khan S, Paty P, Kaul K, Andrade J, White KP, Talamonti M, Posner MC, Hellman S, Weichselbaum RR. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nature Communications 2018, 9: 1793. PMID: 29728604, PMCID: PMC5935683, DOI: 10.1038/s41467-018-04278-6.Peer-Reviewed Original ResearchConceptsColorectal liver metastasesLiver metastasesColorectal cancerOligometastatic colorectal cancerMetastatic colorectal cancerHigh-risk patientsSubset of patientsClinical risk stratificationTreatment of metastasesAngiogenic signatureVEGFA amplificationOligometastatic stateOverall survivalFavorable survivalRisk stratificationAdverse outcomesMetastatic cancerMolecular subtypesFocal therapyMetastasisPatientsMetastatic virulenceMolecular subtypingRobust subtypesCancerDistinctive features of gastrointestinal stromal tumors arising from the colon and rectum
Zhu R, Liu F, Grisotti G, Pérez-Irizarry J, Cha CH, Johnson CH, Boffa DJ, Han D, Johung KL, Zhang Y, Khan SA. Distinctive features of gastrointestinal stromal tumors arising from the colon and rectum. Journal Of Gastrointestinal Oncology 2018, 9: 231-240. PMID: 29755761, PMCID: PMC5934147, DOI: 10.21037/jgo.2017.11.12.Peer-Reviewed Original ResearchRectal gastrointestinal stromal tumorGastric gastrointestinal stromal tumorsGastrointestinal stromal tumorsNational Cancer Data BaseAdjuvant therapyOverall survivalSystemic therapyStromal tumorsCases of GISTColonic gastrointestinal stromal tumorsSmall bowel originAdjuvant systemic therapyWorse overall survivalUnique clinicopathologic featuresBowel originTherapy prolongsClinical characteristicsPatient demographicsLocal excisionPrognostic factorsPropensity matchingSurgical treatmentTreatment guidelinesClinicopathologic featuresClinical care
2017
Post-operative radiotherapy is associated with improved survival in esophageal cancer with positive surgical margins
Gao SJ, Park HS, Corso CD, Rutter CE, Khan SA, Johung KL. Post-operative radiotherapy is associated with improved survival in esophageal cancer with positive surgical margins. Journal Of Gastrointestinal Oncology 2017, 8: 953-961. PMID: 29299354, PMCID: PMC5750177, DOI: 10.21037/jgo.2017.08.12.Peer-Reviewed Original ResearchPost-operative radiotherapyClinical stage INational Cancer Data BaseEarly-stage esophageal cancerOverall survivalPositive surgical marginsPositive marginsUpfront esophagectomyEsophageal cancerStage IImproved survivalSurgical marginsMultivariable Cox regression analysisImproved overall survivalReceipt of chemotherapyCox regression analysisMultivariable logistic regressionEsophageal cancer patientsLog-rank testAdjuvant chemotherapyOS benefitPostoperative chemotherapyPN0 diseaseMultivariable analysisCancer patientsPrognostic signatures of oligometastasis in colorectal cancer liver metastasis.
Khan S, Paty P, Zeng Z, Lu J. Prognostic signatures of oligometastasis in colorectal cancer liver metastasis. Journal Of Clinical Oncology 2017, 35: 3588-3588. DOI: 10.1200/jco.2017.35.15_suppl.3588.Peer-Reviewed Original ResearchColorectal cancer liver metastasesCancer liver metastasesHox gene familyLiver metastasesGene familyLonger recurrence-free survivalUnique molecular subtypePrimary colorectal cancerRecurrence-free survivalSelection of patientsRisk of recurrenceUseful prognostic informationFrozen tumor tissueCRCLM patientsOligometastatic phenotypeMetastasis resectionFree survivalLimited metastasesLiver resectionOverall survivalClinical outcomesWidespread metastasesFurther mechanistic studiesColorectal cancerHOX family members
2015
Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome
Wightman SC, Uppal A, Pitroda SP, Ganai S, Burnette B, Stack M, Oshima G, Khan S, Huang X, Posner MC, Weichselbaum RR, Khodarev NN. Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome. British Journal Of Cancer 2015, 113: 327-335. PMID: 26042934, PMCID: PMC4506383, DOI: 10.1038/bjc.2015.193.Peer-Reviewed Original ResearchConceptsClinical outcomesMetastatic potentialPoor clinical outcomePoor overall survivalMetastatic disease progressionExpression of CXCL10Renal cell carcinomaFunction of CXCL10Increased metastatic potentialIndividual tumor clonesTumor cell growthClinical data setsMetastatic diseaseOverall survivalMetastatic recurrenceCell carcinomaDifferent metastatic abilityCXCR3 pathwayCytokine profilingDisease progressionOncogenic axisCXCR3Metastasis developmentAvailable clinical data setsCXCL10